

Stock Sentiment Analysis Report

Revvity (RVTY)

Analysis Period: 2026-03-16 to 2026-04-15 (30 days)

Generated: 2026-04-15 10:01:17

Executive Summary


Sentiment analysis for Revvity (RVTY) from 2026-03-16 to 2026-04-15. Analyzed 77 items across FDA and news sources.

Sentiment Breakdown

Category	Count	Percentage
Positive	22	28.6%
Negative	17	22.1%
Neutral	38	49.4%
Total	77	100.0%

Overall Sentiment: NEUTRAL

Sentiment Trend Over Time



Key Findings

No key findings available.

Top Positive Events

Title	Source	Date	Score
Nephron Research gets more bullish on Revvity, upg...	news	2026-03-26	0.991
[Latest] Global Environmental Mass Spectrometry Ma...	news	2026-04-02	0.859
Catabolism of extracellular glutathione supplies c...	news	2026-03-18	0.856
Revvity Inc. stock outperforms competitors on stro...	alpha_vantage	2026-04-08	0.711
Revvity Inc. stock outperforms competitors on stro...	alpha_vantage	2026-04-02	0.711

Top Negative Events

Title	Source	Date	Score
The E3 ubiquitin ligase mechanism specifying targe...	news	2026-03-18	-0.778
Ectopic NMDAR expression in cancer unmasks germlin...	news	2026-03-25	-0.660
Feasibility of deep learning-based cancer detectio...	pubmed	2026-04-15	-0.660
A μ -opioid receptor superagonist analgesic with mi...	news	2026-04-01	-0.612
Revvity downgraded to Equal Weight from Overweight...	alpha_vantage	2026-04-14	-0.561